Our Lady of the Lake Cancer Institute patients receiving treatment for late-stage endometrial cancer now have a new standard of care that could greatly enhance the likelihood of remission and recovery thanks to a clinical research trial conducted in part by Our Lady of the Lake Cancer Institute oncologist Sobia Ozair, MD.
Ozair served as a principal investigator on the nationwide study recently published in the New England Journal of Medicine. The study found that adding immunotherapy to standard chemotherapy treatments greatly improved the chances of survival for patients with stage III or IV endometrial cancer (cancers in the inner lining of the uterus).
Ozair has already begun utilizing the new standard of care for her patients, who previously had few alternatives.
Endometrial cancer is the most common cancer of the female reproductive organs, with more than 66,000 women diagnosed in the U.S. each year. According to Ozair, this type of cancer is often not detected until its advanced stages, making treatment more difficult.